Forest Services
Introduction to exRNA and Its Biomedical Significance
Extracellular RNA (exRNA) refers to RNA molecules present outside cells, circulating in bodily fluids such as blood, saliva, and urine. Unlike intracellular RNA, exRNA functions as a signaling molecule involved in intercellular communication and regulation of gene expression. Interest in exRNA surged after 2010, following discoveries of its stability in extracellular vesicles and potential as a non-invasive biomarker. Globally, exRNA research is expanding rapidly, with India emerging as a notable player through government initiatives and increasing patent activity.
The biomedical significance of exRNA lies in its dual role: as a diagnostic tool enabling early disease detection, and as a therapeutic agent, particularly in RNA-based vaccines, gene silencing, and targeted drug delivery. This positions exRNA at the forefront of precision medicine and biopharma innovation.
UPSC Relevance
- GS Paper 3: Science and Technology - Biotechnology, Health Sector Innovations
- GS Paper 2: Governance - Regulatory Frameworks for Clinical Trials and Drug Approval
- Essay: Role of Biotechnology in India’s Healthcare and Economic Growth
Regulatory and Legal Framework Governing exRNA in India
The Drugs and Cosmetics Act, 1940 (amended 2020) governs clinical trials and approval of RNA-based therapeutics under Sections 3 and 3A, mandating rigorous safety and efficacy evaluations. However, no dedicated regulatory guidelines exist specifically for exRNA therapeutics, causing delays in trial approvals and commercialization.
The Indian Patent Act, 1970 (amended 2005), especially Section 3(d), restricts patentability of new forms of known substances unless they show enhanced efficacy. This impacts patent protection for exRNA innovations, often viewed as derivatives of known RNA molecules, complicating intellectual property rights.
The Biomedical Waste Management Rules, 2016 regulate disposal of RNA-based clinical materials, ensuring biosafety during handling of biological waste from RNA diagnostics and therapeutics.
The National Biotechnology Development Strategy 2015-2020 by the Department of Biotechnology (DBT) provides policy guidance promoting biotech innovations, including RNA research, emphasizing public-private partnerships and infrastructure development.
Economic Dimensions of exRNA Research and Industry in India
India’s biotechnology sector was valued at approximately USD 70 billion in 2023, with a projected CAGR of 15% through 2030 (IBEF 2023). The National Biopharma Mission allocated INR 4,500 crore (~USD 600 million) between 2020-2025, focusing heavily on RNA-based therapeutics and gene therapy projects.
India’s share in global RNA therapeutics patents rose by 25% between 2018 and 2023 (WIPO data), reflecting growing innovation capacity. The export of biotech products, including RNA diagnostics, grew 18% in FY 2023, reaching USD 3.5 billion (Department of Commerce, India).
- Global exRNA market projected to reach USD 1.2 billion by 2027 with 16.5% CAGR (MarketsandMarkets, 2023).
- CDSCO-approved exRNA diagnostic kits increased from 2 in 2018 to 12 in 2023.
- ICMR reported 15 ongoing clinical trials involving exRNA-based therapies as of 2023.
Key Institutions Driving exRNA Innovation and Governance
- Department of Biotechnology (DBT): Provides funding, policy direction, and infrastructure support for RNA research.
- Indian Council of Medical Research (ICMR): Oversees clinical trials and ethical standards for RNA therapeutics.
- Council of Scientific and Industrial Research (CSIR): Conducts fundamental research and innovation in exRNA biology.
- Central Drugs Standard Control Organization (CDSCO): Regulates approval of RNA-based drugs and diagnostics.
- Biotech Industry Research Assistance Council (BIRAC): Incubates startups and facilitates commercialization of RNA technologies.
- World Intellectual Property Organization (WIPO): Provides patent data and international IP frameworks relevant to exRNA technologies.
Comparative Analysis: India vs United States in exRNA Development
| Aspect | India | United States |
|---|---|---|
| Government Investment | INR 4,500 crore (~USD 600 million) National Biopharma Mission (2020-25) | Over USD 1 billion via NIH since 2018 |
| Regulatory Framework | General RNA therapeutics under Drugs and Cosmetics Act; no dedicated exRNA guidelines | FDA has specific RNA-based therapeutic guidelines enabling faster approvals |
| Market Size (2023) | USD 3.5 billion biotech exports including RNA therapeutics | USD 5 billion exRNA market |
| Clinical Trials | 15 ongoing exRNA-based trials (ICMR Registry 2023) | Multiple approved RNA therapeutics including mRNA vaccines and siRNA drugs |
| Patent Filings Growth (2018-2023) | 25% increase in RNA therapeutics patents (WIPO) | Higher volume and faster patent grants due to clearer IP policies |
Challenges and Critical Gaps in India’s exRNA Ecosystem
- Lack of dedicated regulatory framework for RNA-based therapeutics and diagnostics delays clinical trial approvals and market entry.
- Section 3(d) of the Patent Act restricts patentability, discouraging private sector investment in exRNA innovation.
- Limited infrastructure for large-scale RNA manufacturing and quality control compared to global leaders.
- Insufficient coordination between research institutions and industry hampers rapid translation from lab to market.
- Ethical and biosafety concerns around RNA therapeutics require clearer guidelines and public awareness.
Significance and Way Forward
- Establish a dedicated regulatory framework for exRNA therapeutics and diagnostics to streamline approvals and commercialization.
- Revise patent laws to balance innovation incentives with public health imperatives, particularly clarifying the scope of Section 3(d) for RNA technologies.
- Increase public and private investment in RNA manufacturing infrastructure and skilled workforce development.
- Enhance collaboration between DBT, ICMR, CSIR, and industry through platforms like BIRAC to accelerate innovation cycles.
- Implement robust biosafety and ethical guidelines specific to RNA-based clinical materials and trials.
- Leverage India’s growing biotech export capacity to capture larger shares of the global exRNA market.
- exRNA is primarily involved in intracellular gene expression regulation.
- exRNA can be found circulating in bodily fluids such as blood and saliva.
- exRNA-based diagnostic kits have seen increased approvals by CDSCO in recent years.
Which of the above statements is/are correct?
- Section 3(d) of the Indian Patent Act restricts patentability of new forms of known substances without enhanced efficacy.
- Section 3(d) facilitates faster patent grants for RNA-based innovations.
- Section 3(d) impacts private sector investment in RNA therapeutics.
Which of the above statements is/are correct?
What is extracellular RNA (exRNA) and how does it differ from intracellular RNA?
Extracellular RNA (exRNA) comprises RNA molecules found outside cells, circulating in bodily fluids and involved in intercellular communication. Intracellular RNA functions within cells, regulating gene expression and protein synthesis. exRNA is stable in extracellular vesicles, enabling its use as a biomarker and therapeutic agent.
Which Indian laws govern the clinical trials and approval of RNA-based therapeutics?
The Drugs and Cosmetics Act, 1940 (amended 2020) regulates clinical trials and approval of RNA therapeutics under Sections 3 and 3A. The Biomedical Waste Management Rules, 2016 govern disposal of RNA-based clinical materials.
How does Section 3(d) of the Indian Patent Act affect RNA therapeutics innovation?
Section 3(d) restricts patentability of new forms of known substances without enhanced efficacy. This limits patent protection for RNA therapeutics that are derivatives of known RNA molecules, potentially discouraging private investment in innovation.
What are the key institutions involved in exRNA research and regulation in India?
Key institutions include DBT (funding and policy), ICMR (clinical trials and ethics), CSIR (basic research), CDSCO (drug approvals), and BIRAC (startup incubation).
How does India’s exRNA ecosystem compare with that of the United States?
The US invests over USD 1 billion in exRNA research with dedicated FDA guidelines, resulting in multiple approved RNA therapeutics and a USD 5 billion market. India’s ecosystem is nascent with growing investments (~USD 600 million), lacks RNA-specific regulations, but shows rapid patent growth and increasing exports.
About LearnPro Editorial Standards
LearnPro editorial content is researched and reviewed by subject matter experts with backgrounds in civil services preparation. Our articles draw from official government sources, NCERT textbooks, standard reference materials, and reputed publications including The Hindu, Indian Express, and PIB.
Content is regularly updated to reflect the latest syllabus changes, exam patterns, and current developments. For corrections or feedback, contact us at admin@learnpro.in.